PortalPublikationenMulti-omic based molecular profiling of advanced cancer iden...

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients

Standard

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients. / Samsen, Alexandra; von der Heyde, Silvia; Bokemeyer, Carsten; David, Kerstin A; Flath, Bernd; Graap, Max; Grebenstein, Bianca; Heflik, Ludger; Hollburg, Wiebke; Layer, Peter; von Leitner, Eike; Overkamp, Friedrich; Saeger, Wolfgang; Schneider, Sandra; von Seydewitz, Cay-Uwe; Stang, Axel; Stein, Alexander; Zornig, Carsten; Juhl, Hartmut.

in: ONCOTARGET, Jahrgang 9, Nr. 78, 05.10.2018, S. 34794-34809.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Samsen, A, von der Heyde, S, Bokemeyer, C, David, KA, Flath, B, Graap, M, Grebenstein, B, Heflik, L, Hollburg, W, Layer, P, von Leitner, E, Overkamp, F, Saeger, W, Schneider, S, von Seydewitz, C-U, Stang, A, Stein, A, Zornig, C & Juhl, H 2018, 'Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients', ONCOTARGET, Jg. 9, Nr. 78, S. 34794-34809. https://doi.org/10.18632/oncotarget.26198

APA

Samsen, A., von der Heyde, S., Bokemeyer, C., David, K. A., Flath, B., Graap, M., Grebenstein, B., Heflik, L., Hollburg, W., Layer, P., von Leitner, E., Overkamp, F., Saeger, W., Schneider, S., von Seydewitz, C-U., Stang, A., Stein, A., Zornig, C., & Juhl, H. (2018). Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients. ONCOTARGET, 9(78), 34794-34809. https://doi.org/10.18632/oncotarget.26198

Vancouver

Samsen A, von der Heyde S, Bokemeyer C, David KA, Flath B, Graap M et al. Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients. ONCOTARGET. 2018 Okt 5;9(78):34794-34809. https://doi.org/10.18632/oncotarget.26198

Bibtex

@article{29af50dd7da04537a2506d9c0c2fa94f,
title = "Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients",
abstract = "A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. At genomic level, 50 oncogenes and tumor suppressor genes were analyzed. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell in two equal-sized groups. One group received targeted therapies while the other did not. Following six months of treatment, disease control was achieved by 49% of patients receiving targeted therapy (complete remission, 14%; partial remission, 21%; stable disease, 14%; disease progression, 36%; death, 14%) and 21% of patients receiving non-targeted therapy (stable disease, 21%; disease progression, 64%; death, 14%). Individual patients experienced dramatic responses to a therapy which otherwise would not have been applied. This approach clarifies the value of multi-omic molecular profiling for cancer diagnostics.",
keywords = "Journal Article",
author = "Alexandra Samsen and {von der Heyde}, Silvia and Carsten Bokemeyer and David, {Kerstin A} and Bernd Flath and Max Graap and Bianca Grebenstein and Ludger Heflik and Wiebke Hollburg and Peter Layer and {von Leitner}, Eike and Friedrich Overkamp and Wolfgang Saeger and Sandra Schneider and {von Seydewitz}, Cay-Uwe and Axel Stang and Alexander Stein and Carsten Zornig and Hartmut Juhl",
year = "2018",
month = oct,
day = "5",
doi = "10.18632/oncotarget.26198",
language = "English",
volume = "9",
pages = "34794--34809",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "78",

}

RIS

TY - JOUR

T1 - Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients

AU - Samsen, Alexandra

AU - von der Heyde, Silvia

AU - Bokemeyer, Carsten

AU - David, Kerstin A

AU - Flath, Bernd

AU - Graap, Max

AU - Grebenstein, Bianca

AU - Heflik, Ludger

AU - Hollburg, Wiebke

AU - Layer, Peter

AU - von Leitner, Eike

AU - Overkamp, Friedrich

AU - Saeger, Wolfgang

AU - Schneider, Sandra

AU - von Seydewitz, Cay-Uwe

AU - Stang, Axel

AU - Stein, Alexander

AU - Zornig, Carsten

AU - Juhl, Hartmut

PY - 2018/10/5

Y1 - 2018/10/5

N2 - A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. At genomic level, 50 oncogenes and tumor suppressor genes were analyzed. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell in two equal-sized groups. One group received targeted therapies while the other did not. Following six months of treatment, disease control was achieved by 49% of patients receiving targeted therapy (complete remission, 14%; partial remission, 21%; stable disease, 14%; disease progression, 36%; death, 14%) and 21% of patients receiving non-targeted therapy (stable disease, 21%; disease progression, 64%; death, 14%). Individual patients experienced dramatic responses to a therapy which otherwise would not have been applied. This approach clarifies the value of multi-omic molecular profiling for cancer diagnostics.

AB - A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. At genomic level, 50 oncogenes and tumor suppressor genes were analyzed. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell in two equal-sized groups. One group received targeted therapies while the other did not. Following six months of treatment, disease control was achieved by 49% of patients receiving targeted therapy (complete remission, 14%; partial remission, 21%; stable disease, 14%; disease progression, 36%; death, 14%) and 21% of patients receiving non-targeted therapy (stable disease, 21%; disease progression, 64%; death, 14%). Individual patients experienced dramatic responses to a therapy which otherwise would not have been applied. This approach clarifies the value of multi-omic molecular profiling for cancer diagnostics.

KW - Journal Article

U2 - 10.18632/oncotarget.26198

DO - 10.18632/oncotarget.26198

M3 - SCORING: Journal article

C2 - 30410678

VL - 9

SP - 34794

EP - 34809

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 78

ER -